PT  - JOURNAL ARTICLE
AU  - Kurita, Junko
AU  - Sugawara, Tamie
AU  - Ohkusa, Yasushi
TI  - Huge Excess Mortality due to the delta strain of COVID-19 in Japan in August, 2021
AID  - 10.1101/2020.07.09.20143164
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.07.09.20143164
4099  - http://medrxiv.org/content/early/2021/10/25/2020.07.09.20143164.short
4100  - http://medrxiv.org/content/early/2021/10/25/2020.07.09.20143164.full
AB  - Background No remarkable excess mortality attributable to COVID-19 has been observed in Japan until the delta strain of COVID-19 emerged.Object We sought to quantify high pathogenicity of the delta strain using the National Institute of Infectious Diseases (NIID) model.Method We applied the NIID model to deaths of all causes from 1987 up through August, 2021 for the whole of Japan and up through May, 2021 for Tokyo.Results Results in Japan show 4105 excess mortality in August, 2021 in Japan. It was estimated as 3.8% of the baseline.Discussion and Conclusion We found substantial excess mortality since the outbreak of COVID-19 had emerged in August, 2021, in Japan. It might be due to spread of delta strain at that timeCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All information used for this study has been published. There is therefore no ethical issue related to this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMinistry of Health, Labour and Welfare. Preliminary statistics on demographics https://www.mhlw.go.jp/toukei/list/81-1a.html